A practical reference on blood-brain barrier: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Derived from the seven-residue sequence |
| Molecular weight | About 751.9 g/mol | Average mass; the monoisotopic value is slightly lower |
| Residue count | Seven amino acids | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent compound | Tuftsin (Thr-Lys-Pro-Arg) | Selank extends tuftsin at the C-terminus |
| Compound class | Synthetic short peptide | Studied in a research setting; not a licensed drug in most markets |
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
== Further reading == Jablonski, S.; Leonard, R.M.; National Library of Medicine (U.S.) (1961). Russian Drug Index. Public Health Service publication. U.S. Department of Health, Education, and Welfare, Public Health Service. Retrieved 5 October 2024.
De Lima presented as witness an alleged member of Davao City-based vigilante group Davao Death Squad, Edgar Matobato, who testified that Duterte was involved in extrajudicial killings in the city. Duterte dismissed the allegations as fabricated, and the Senate committee formally terminated the inquiry on October 13, 2016, citing a lack of corroborating evidence. Shortly after, Duterte implicated De Lima in the illegal drug trade during her tenure as Justice Secretary under the Aquino III administration. Though De Lima denied the claims, she was later imprisoned in February 2017 due to the drug charges. Two months later, Matobato's lawyer, Jude Josue Sabio, filed charges for crimes against humanity with the International Criminal Court against Duterte and 11 other officials. Responding to public clamor, in October 2017, Duterte designated the Philippine Drug Enforcement Agency to lead anti-drug operations and temporarily barred the police from joining the raids. Through an executive order he issued in October 2018, Duterte instituted a more balanced approach to the drug problem by establishing the Philippine Anti-Illegal Drugs Strategy, which ordered all government departments and state universities and colleges to implement their own strategies in tackling the country's illegal drug trade; the order also urged local government units, non-government organizations, and private institutions to support and implement the Strategy.
In response to the potential ban, many users signed up for the Chinese app Xiaohongshu (Chinese: 小红书), known internationally as REDnote. On 18 January 2025, hours before the bill went into effect, TikTok became unavailable across the country. The next day, TikTok restored access to their service after re-elected US President Donald Trump assured TikTok he would not enforce the law. President Trump signed an executive order on 20 January 2025, delaying the enforcement of the TikTok ban by 75 days. In April 2025, President Trump signed another executive order further delaying the enforcement of the TikTok ban by 75 days, and did so again in June 2025 with a 90-day extension. The Department of Justice's Office of Legal Counsel determined that TikTok USDS, the version of TikTok operated by the TikTok U.S. Data Security Joint Venture, was not subject to the No TikTok on Government Devices Act, thereby permitting employees to use TikTok on government devices, subject to agency discretion and workplace policies.
=== Category:EC 5.1 (racemases and epimerases) === Category:EC 5.1.1 Amino-acid racemase: Phenylalanine racemase (ATP-hydrolysing) Serine racemase Category:EC 5.1.2 Mandelate racemase Category:EC 5.1.3 UDP-glucose 4-epimerase Category:EC 5.1.99 Methylmalonyl CoA epimerase
Sources: en.wikipedia.org
Japan has the highest number of 7-Eleven locations in the world, as of the company's 85,000+ stores around the globe, 21,668 stores (nearly 25% of global stores) are in Japan, with 2,824 stores in Tokyo alone. Japanese 7-Eleven stores often bear the name of its holding company Seven & I Holdings—in fact, Seven & I's subsidiary Seven-Eleven Japan, the master franchisee for Japan, is the direct parent company of 7-Eleven, Inc. On September 1, 2005, Seven & i Holdings Co., Ltd., a new holding company, became the parent company of 7-Eleven, Ito-Yokado, and Denny's Japan. As of July 2019, 7-Eleven has stores in all 47 prefectures of Japan with the opening of 14 new locations in Okinawa Prefecture. The aesthetics of the store are somewhat different from that of 7-Eleven stores in other countries as the stores offer a wider selection of products and services. 7-Eleven stores in Japan are also popular among tourists from other countries, as the Seven Bank automated teller machines at branches will accept foreign debit and credit cards for withdrawing cash in Japanese yen. Following the example of other convenience stores in Japan, 7-Eleven has solar panels and LEDs installed in about 1,400 of its stores. In July 2019, 7-Eleven launched then almost immediately suspended a mobile payment service, 7pay. The service was hacked upon launch, and attackers were able to spend money from affected customers' accounts.
An analysis of the official data from the late 1980s showed that after worsening in the late 1970s and the early 1980s, adult mortality began to improve again. The infant mortality rate increased from 24.7 in 1970 to 27.9 in 1974. Some researchers regarded the rise as mostly real, a consequence of worsening health conditions and services. The rises in both adult and infant mortality were not explained or defended by Soviet officials, and the Soviet government stopped publishing all mortality statistics for ten years. Soviet demographers and health specialists remained silent about the mortality increases until the late 1980s, when the publication of mortality data resumed, and researchers could delve into the real causes.
== Epidemiology == Hereditary spherocytosis is a heritable hemolytic disorder, affecting 1 in 2,000 people of Northern European ancestry. According to Harrison's Principles of Internal Medicine, the frequency is at least 1 in 5,000 within the United States of America. While HS is most commonly (though not exclusively) found in Northern European and Japanese families, an estimated 25% of cases are due to spontaneous mutations.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.
Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.
No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.